Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

New Approaches in Visceral Leishmaniasis Prevention: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine

Version 1 : Received: 30 January 2024 / Approved: 31 January 2024 / Online: 31 January 2024 (05:56:13 CET)

A peer-reviewed article of this Preprint also exists.

de Oliveira, D.S.; Zaldívar, M.F.; Gonçalves, A.A.M.; Resende, L.A.; Mariano, R.M.S.; Pereira, D.F.S.; Conrado, I.S.S.; Costa, M.A.F.; Lair, D.F.; Vilas Boas, D.F.; Nakasone, E.N.; Ameno, I.S.; Goes, W.M.; Silveira-Lemos, D.; Galdino, A.S.; Nagem, R.A.P.; Dutra, W.O.; Giunchetti, R.C. New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine. Vaccines 2024, 12, 271. de Oliveira, D.S.; Zaldívar, M.F.; Gonçalves, A.A.M.; Resende, L.A.; Mariano, R.M.S.; Pereira, D.F.S.; Conrado, I.S.S.; Costa, M.A.F.; Lair, D.F.; Vilas Boas, D.F.; Nakasone, E.N.; Ameno, I.S.; Goes, W.M.; Silveira-Lemos, D.; Galdino, A.S.; Nagem, R.A.P.; Dutra, W.O.; Giunchetti, R.C. New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine. Vaccines 2024, 12, 271.

Abstract

Prophylactic vaccines are important in the control of visceral leishmaniasis (VL) and as economic measures for public health. Despite the efforts to develop a vaccine against human VL caused by Leishmania infantum, none is available, and the focus has shifted to developing vaccines against canine visceral leishmaniasis (CVL). Currently, commercially available vaccines are targeted at CVL but are not effective. Different strategies have been applied in developing and improving vaccines, such as using chimeric proteins to expand vaccine coverage. The search for patents can be a way of tracking vaccines that have the potential to be marketed. In this context, the present work presents a summary of immunological aspects relevant to VL vaccine development with a focus on the composition of chimeric protein vaccines for CVL deposited in patent banks as an important approach for biotechnological development. The resulting data could facilitate the screening and selection of antigens to compose vaccine candidates with high performance against VL.

Keywords

Visceral Leishmaniasis; vaccine; chimeric proteins; patents

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.